ATC Group: A16AB11 Taliglucerase alfa

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A16AB11 in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A16 Other alimentary tract and metabolism products
3 A16A Other alimentary tract and metabolism products
4 A16AB Enzymes
5 A16AB11

Active ingredients in A16AB11

Active Ingredient Description
Taliglucerase alfa

Taliglucerase alfa, a long term enzyme replacement therapy, is a recombinant analog of human lysosomal glucocerebrosidase that catalyzes the hydrolysis of glucocerebroside to glucose and ceramide, reducing the amount of accumulated glucocerebroside. It is used for the treatment of patients with a confirmed diagnosis of Type 1 Gaucher disease.

Related product monographs

Title Information Source Document Type  
ELELYSO Powder for solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

Canada (CA)

Israel (IL)

New Zealand (NZ)

South Africa (ZA)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.